3SBIO INC. |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.785 EUR | 0.00% |
|
+3.97% | -7.65% |
| 06-25 | 3Sbio Inc. Declares Final Dividend for the Year Ended 31 December 2023, Payable on 5 August 2024 | CI |
| 06-25 | 3Sbio Inc. Announces Board Changes | CI |
| Sales 2024 * | 8.73B 1.2B 1.1B 1.64B | Sales 2025 * | 9.5B 1.31B 1.2B 1.79B | Capitalization | 14.44B 1.99B 1.82B 2.72B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.95B 269M 246M 368M | Net income 2025 * | 2.15B 296M 271M 405M | EV / Sales 2024 * | 1.8 x |
| Net Debt 2024 * | 1.26B 173M 158M 237M | Net cash position 2025 * | 1.06B 146M 133M 199M | EV / Sales 2025 * | 1.41 x |
| P/E ratio 2024 * |
8.05
x | P/E ratio 2025 * |
7.32
x | Employees | - |
| Yield 2024 * |
3.47% | Yield 2025 * |
4.01% | Free-Float | 71.66% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | +3.97% | ||
| Current month | +6.08% | ||
| 1 month | +3.97% | ||
| 3 months | +14.60% | ||
| 6 months | +1.95% | ||
| Current year | -7.65% |
1 week
0.76
0.79
1 month
0.730.79
| Managers | Title | Age | Since |
|---|---|---|---|
Jing Lou
CEO | Chief Executive Officer | 61 | 92-12-31 |
Xiang He
DFI | Director of Finance/CFO | - | 23-07-02 |
Dong Mei Su
BRD | Director/Board Member | 54 | 12-06-10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jing Lou
CEO | Chief Executive Officer | 61 | 92-12-31 |
Dong Mei Su
BRD | Director/Board Member | 54 | 12-06-10 |
Tian Ruo Pu
BRD | Director/Board Member | 55 | 15-05-31 |
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 0.785 | 0.00% |
| 24-07-16 | 0.785 | 0.00% |
| 24-07-15 | 0.785 | 0.00% |
| 24-07-12 | 0.785 | +1.95% |
| 24-07-11 | 0.77 | +1.32% |
Real-time BOERSE MUENCHEN, July 17, 2024 at 10:13 am
More quotes
3SBio Inc. is an investment holding company mainly engaged in the the development, production, marketing and sale of pharmaceutical products. The Companyâs main products include recombinant human thrombopoietin (rhTPO) products, tumor necrosis factor (TNF)αinhibitor products and recombinant human erythropoietin (rhEPO) products. The products are sold under the name of TPIAO, Yisaipu, EPIAO and SEPO. The Company distributes its products within the domestic market and to overseas markets, including Sri Lanka, Dominican Republic and Thailand. The Companyâs subsidiaries include Collected Mind Limited, Hongkong Sansheng Medical Limited and Shenyang Sunshine Pharmaceutical Co., Ltd.. Through its subsidiaries, the Company is engaged in project management and consultation.
Sector
Pharmaceuticals
Calendar
2024-08-20
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
6.131
CNY
Average target price
7.032
CNY
Spread / Average Target
+14.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.46% | 100B | |
| +8.42% | 42.34B | |
| -11.80% | 32.76B | |
| +79.85% | 29.46B | |
| -11.71% | 16.31B | |
| +2.93% | 14.39B | |
| -6.77% | 12.23B | |
| +177.16% | 10.47B | |
| +1.50% | 8.97B |
- Stock Market
- Equities
- 1530 Stock
- 83B Stock
